Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPN 217

Next Previous
Search
Drug Profile

HPN 217

Alternative Names: BCMA TriTAC; HPN-217

Latest Information Update: 15 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harpoon Therapeutics
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies; Trispecific antibodies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 11 Mar 2024 Harpoon Therapeutics has been acquired by Merck and Co
  • 11 Dec 2023 Interim efficacy, adverse events and pharmacokinetics data from a phase-I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 28 Sep 2023 Interim efficacy and adverse events data from phase I trial in multiple myeloma released by Harpoon Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top